6996 — Antengene Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$1.39bn
- CNY105.34m
Brief: Antengene Corp Announces Approval Of Phase Ii Study Of Selinexor By Nmpa
Brief: Antengene Corp Posts HY Adjusted Loss Of RMB209.9 Mln
Brief: Antengene Corp Says South Korean Ministry Of Food And Drug Safety Approved NDA For Atg-010 (Selinexor)
Brief: Antengene Corporation Says Yiteng Liu Will Not Seek Re-Appointment As Executive Director
Brief: Antengene Corp Says A Member Of Group Has Entered Into An Exclusive, Worldwide License Agreement With Calithera Biosciences
Brief: Calithera Biosciences And Antengene Enter Worldwide License Agreement For Development & Commercialization Of Cb-708
Brief: Antengene Corp Announces NMPA Approval Of IND Applications For Phase Ib/Ii Clinical Trial Of Eltanexor In Advanced Solid Tumors
Brief: Antengene Announces IND Approval In China For A Global Phase III Trial Of Selinexor In Advanced Or Recurrent Endometrial Cancer
Brief: Antengene Got NMPA Approval For Phase III Clinical Trial Of Selinexor
Brief: Antengene Says Unit Entered Into Framework Agreement
Brief: Antengene Corp Says NMPA Approved Application For ATG-019 In Patients With Advanced Solid Tumors
Brief: Antengene Corp FY Loss And Total Comprehensive Loss Attributable RMB2.93 Billion
Brief: Antengene Corp - Acceptance Of NDA By Nmpa For Atg-010 (Selinexor) For Treatment Of Relapsed/Refractory Multiple Myeloma
Brief: Antengene Announces NMPA Approval Of IND Application For ATG-010 In Combination With R-GDP
Brief: Antengene Says Its U.S. Partner, Karyopharm Therapeutics Inc., Received FDA Approval Of Xpovio As Treatment For Patients With Multiple Myeloma After At Least One Prior Therapy
Brief: Antengene Announces Approval Of IND Application In China For Phase 3 Clinical Trial Of ATG-010
Brief: Antengene Corp Says Unit Got A Government Grant Of Rmb10.9 Million In PRC
Brief: Antengene Says Submitted New Drug Applications For Xpovio
Brief: Antengene Corp Says Unit Got Government Grant Of Rmb26.8 Million In PRC